OTC Watch

All stocks / LMMY

Exousia Bio, Inc. LMMY

Exousia Bio (LMMY): shares outstanding up 575% in a year, a late 10-Q notice in April 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

DilutionEstimated floatLate filing Pink LimitedFlorida, USA
Live quote on OTC Markets

Market listing

Full name
L A M Y
Market tier
OTC Pink Limited
Trading status
Active
Last trade
Nov 11
Source: Stockwatch, 2026-11-17

News headlines

Exousia Bio Nearing Completion of Milestone Multimillion-Dollar Capital Investment
2026-08-04 10:59 · News Release
Renowned Immunologist and Urological Surgeon Dr. Marvin Hausman Featured in New Exousia Bio, Inc. Interview
2025-12-04 08:30 · News Release
Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms
2025-12-02 13:45 · News Release
LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.
2025-12-02 10:28 · News Release
Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value
2025-11-17 15:40 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-05-31
The report says
Revenue
$3,750
Net income
$51,395
What it means

It earned more than it spent

Steady

After all costs, the company kept $51,395 as profit in the year.

The report says
Cash and cash equivalents
$0
Net cash used in operating activities
($4,528)
What it means

The cash could run out soon

Under strain

It had $0 in the bank and used about $377 a month. At that pace the money lasts less than a month unless it borrows or sells more shares.

What this adds up to

1 of 2 checks show strain. The cash could run out soon. These are facts from the company's own reports, not a recommendation.

Signals

Dilution2026-06-15

Shares outstanding rose from 7,777,000 (2025-05-31) to 52,500,000 (2026-06-15), up 575%.

Rule: Shares outstanding up 20% or more in 12 months. Source record

Estimated float2026-06-15

Estimated float about 52,500,000 shares as of 2026-06-15: 52,500,000 outstanding minus 0 held by 0 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Late filing2026-04-14

Filed NT 10-Q on 2026-04-14: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Late filing2026-01-15

Filed NT 10-Q on 2026-01-15: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Shares outstanding

Source: SEC filings
2025-08-31
7.8M
2025-10-17
7.8M
2025-11-17
7.8M
2025-11-30
70.0M
2026-02-28
70.0M
2026-03-17
73.5M
2026-03-31
70.0M
2026-06-15
52.5M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-08-31 15-12GTERMINATION OF REGISTRATION STMT
2026-06-16 10-QQUARTERLY REPORT FOR FEB 2026
2026-04-14 NT 10-QEXTENSION
2026-03-17 10-QFORM 10-Q FOR NOV 2025
2026-01-15 NT 10-QEXTENSION
2025-11-17 10-Q10-Q
2025-11-17 8-KFORM 8-K

Common questions about LMMY

Does LMMY file reports with the SEC?

Yes. Exousia Bio files with the SEC under company number 0001939937. The most recent filing we hold is a 15-12G dated 2026-08-31.

Source record

How many LMMY shares are outstanding?

52,500,000 shares as of 2026-06-15, as reported to the SEC. That is up 575% from 7,777,000 on 2025-05-31.

Source record

Has LMMY filed reports late?

Yes. In the last 12 months it filed 2 late-filing notices, most recently a NT 10-Q on 2026-04-14. A notice means a report was not ready on time; check whether the report followed.

Source record

Is Exousia Bio making money?

After all costs, the company kept $51,395 as profit in the year. (Annual figures to 2025-05-31. Facts from the company's own report, not a recommendation.)

Source record